A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Inclusion Criteria:

* Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
* CD19+ B cell count ≥40 cells/μL
* UPCR ≥2.0 g/g
* eGFR ≥35 mL/min/1.73 m²
* Stable RAAS inhibitor therapy
* Blood pressure \<150/90 mmHg at baseline
* Adequate hematologic, hepatic, and renal function
* Willing to use effective contraception (both sexes)
* Other inclusion criteria may apply

Exclusion Criteria:

* Secondary Membranous Nephropathy
* Rapidly progressive glomerulonephritis or other glomerulopathies
* Prior B cell-depleting therapy within 24 weeks
* Recent use of immunosuppressants
* Active or high-risk infections
* History of malignancy
* Pregnancy or breastfeeding
* Recent major surgery or hospitalization
* Other exclusion criteria may apply